期刊文献+

基质金属蛋白酶/基质金属蛋白酶组织抑制剂系统与糖尿病眼部并发症 被引量:3

Matrix metalloproteinases/tissue inhibitors of metalloproteinase system and diabetic ocular complications
下载PDF
导出
摘要 基质金属蛋白酶/基质金属蛋白酶组织抑制剂(MMPs/TIMPs)系统是降解和重塑细胞外基质(ECM)最重要的酶系统,它参与调节眼的一些生理和病理过程,如眼的发育、炎症、伤口愈合、新生血管形成、肿瘤转移等,与多种眼病,如增生性玻璃体视网膜病变、增生型糖尿病视网膜病变、糖尿病性白内障、孔源性视网膜脱离、视网膜母细胞瘤、年龄相关性黄斑变性、眼外伤、青光跟等的发生密切相关.就MMPs/TIMPs系统的生物学特性及其在糖尿病眼部并发症研究方面的应用进行综述. The matrix metalloproteinases/tissue inhibitors of metalloproteinase (MMPs/TIMPs) system plays an important role in the degradation and remodel of the extracellular matrix (ECM).MMPs/TIMPs system is associated with ocular physiological process,such as ocular growth and development,etc.Also,MMPs/TIMPs system is involved in ocular pathological process including inflammation,wound healing,neoangiogenesis,tumor invasion and metastasis.MMPs/TIMPs system also participats in the formation of some ophthalmic diseases such as proliferative vitreoretinopathy (PVR),proliferative diabetic retinopathy (PDR),diabetic cataract,rhegmatogenous retinal detachment (RRD),retinoblastoma (RB),age-related macular degeneration (AMD),ocular trauma,and glaucoma.This review attempts to elaborate the biological characteristics of MMPs/TIMPs,and the current researches of MMPs/ TIMPs system in the diabetic ocular complications,focusing on diabetic retinopathy,cataract and keratopathy.
作者 任美侠 周健
出处 《中华实验眼科杂志》 CAS CSCD 北大核心 2014年第9期860-864,共5页 Chinese Journal Of Experimental Ophthalmology
基金 国家自然科学基金项目(30672292) 新世纪优秀人才支持计划项目(NCET-06-932) 西京医院助推计划项目(XJZT09D02)
关键词 基质金属蛋白酶 基质金属蛋白酶组织抑制剂 糖尿病 并发症 视网膜病变 白内障 角膜病变 Matrix metalloproteinase Tissue inhibitior of metalloproteinase Diabetic mellitus/complication Retinopathy Cataract Keratopathy
  • 相关文献

二级参考文献13

  • 1张兴儒,许琰,李青松,刘晔翔,刘祖国,沈江帆,蔡瑞霞,俞彰.结膜松弛症临床与基础研究[J].中国实用眼科杂志,2005,23(1):83-87. 被引量:47
  • 2陈兴雅,沈庆乐,张存琪.血清基质金属蛋白酶与糖尿病血管病变的关系[J].中国误诊学杂志,2005,5(2):248-249. 被引量:4
  • 3郑卫东,徐国兴,胡建章,郑学栋,林雯福.基质金属蛋白酶-1及其抑制剂和转化生长因子-β1在翼状胬肉中的表达及意义[J].眼视光学杂志,2006,8(1):46-48. 被引量:4
  • 4Meller D,Scheffer CG,Tseng P.Conjunctivochalasis:Literature review and possible pathophysiology[J].Surv Ophthalmol,1998,43(3):225-232.
  • 5Lobmann R,Ambrosch A,Schultz G,et al.Expression of matrix-metalloproteinnases and their inhibitors in the wounds of diabetic and nonidabetic patients[J].Diabetologia,2002,45:1011-1016.
  • 6Li DQ,Meller D,Liu YQ,et al.Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts[J].Invest Ophthalmol Vis Sci,2000,41(2):404–410.
  • 7Koya D,King GL.Protein kinase C activation and the development of diabetic complication[J].Diabetes,1998,47(6):859-866.
  • 8Singh R,Song RH,Alavi N,et al.High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1[J].Exp Nephrol,2001,9(4):249-257.
  • 9Mizuiri S,Yoshikawa H,Tanegashima M,et al.Renal ACE immunohistochemical localization in NIDDM patients with nephropathy[J].Am J Kidney Dis,1998,31(2):301-307.
  • 10钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志,2000,8(1):5-6. 被引量:2313

共引文献4

同被引文献36

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部